S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
OTCMKTS:SFOSF

Shanghai Fosun Pharmaceutical (Group) (SFOSF) Stock Price, News & Analysis

$1.53
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$1.53
$1.53
50-Day Range
$1.52
$1.90
52-Week Range
$1.52
$3.03
Volume
N/A
Average Volume
10,144 shs
Market Capitalization
N/A
P/E Ratio
1.31
Dividend Yield
17.62%
Price Target
N/A

About Shanghai Fosun Pharmaceutical (Group)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, anti-infection, API's and intermediate, metabolism, alimentary system, cardiovascular and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services, and investment management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

SFOSF Stock Price History

SFOSF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive SFOSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shanghai Fosun Pharmaceutical (Group) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:SFOSF
CIK
N/A
Fax
N/A
Employees
38,399
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Kexin Wang (Age 59)
    Executive Co-Chairman
    Comp: $2.7M
  • Mr. Yifang Wu (Age 55)
    Executive Chairman
    Comp: $1.76M
  • Mr. Deyong Wen (Age 53)
    Joint President,CEO & Executive Director
    Comp: $1.1M
  • Ms. Xiaohui Guan (Age 53)
    Executive Vice Chairman
    Comp: $1.2M

SFOSF Stock Analysis - Frequently Asked Questions

Should I buy or sell Shanghai Fosun Pharmaceutical (Group) stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shanghai Fosun Pharmaceutical (Group) in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SFOSF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SFOSF, but not buy additional shares or sell existing shares.
View SFOSF analyst ratings
or view top-rated stocks.

How have SFOSF shares performed in 2024?

Shanghai Fosun Pharmaceutical (Group)'s stock was trading at $2.19 at the beginning of 2024. Since then, SFOSF shares have decreased by 30.0% and is now trading at $1.5320.
View the best growth stocks for 2024 here
.

Are investors shorting Shanghai Fosun Pharmaceutical (Group)?

Shanghai Fosun Pharmaceutical (Group) saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,886,200 shares, an increase of 46.5% from the March 15th total of 1,287,900 shares. Based on an average daily trading volume, of 25,200 shares, the short-interest ratio is currently 74.8 days.
View Shanghai Fosun Pharmaceutical (Group)'s Short Interest
.

Is Shanghai Fosun Pharmaceutical (Group) a good dividend stock?

Shanghai Fosun Pharmaceutical (Group) (OTCMKTS:SFOSF) pays an annual dividend of $0.27 per share and currently has a dividend yield of 1.21%. The dividend payout ratio is 23.08%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Shanghai Fosun Pharmaceutical (Group)?

Shares of SFOSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SFOSF) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners